The challenge of optimizing androgen deprivation therapy (ADT) for prostate cancer has been illustrated by two recent papers. A preclinical study demonstrated that the effects of androgen deprivation on prostatic neoplastic tissue are not necessarily beneficial and a large database analysis showed that practice patterns of ADT are not always in line with recommended guidelines.